Compile Data Set for Download or QSAR
Report error Found 26 Enz. Inhib. hit(s) with all data for entry = 9028
TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM436056(US10611770, Compound 17 | 4-[7-({7-[2-Methoxy-4-tr...)
Affinity DataIC50: 2.10nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM436067(US10611770, Compound 31 | 4-[7-({8-[2-Methoxy-4-(t...)
Affinity DataIC50: 2.30nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM377011(US10259816, Compound 33 | 3-Methoxy-4-(2-{[4-(pipe...)
Affinity DataIC50: 2.5nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM377016(US10259816, Compound 42 | N-[7-(2-methoxyphenyl)-6...)
Affinity DataIC50: 2.70nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM376996(7-(2-Methylphenyl)-N-[4-(piperidin-4-yl)-2,3-dihyd...)
Affinity DataIC50: 3.30nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM377014(US10259816, Compound 37 | 4-[7-({8-[2-Methoxy-4-tr...)
Affinity DataIC50: 3.30nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM377013(US10259816, Compound 35 | 8-(4-Methylsulfonyl-2-me...)
Affinity DataIC50: 3.40nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM377005(US10259816, Compound 27 | 8-(4-Fluoro-2-methoxyphe...)
Affinity DataIC50: 5.10nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM436049(US10611770, Compound 1 | N-(2-(2-((2-Methoxy-4-(pi...)
Affinity DataIC50: 5.5nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM376994(N-[2-Methoxy-4-(piperidin-4-yl)phenyl]-7-(2-methox...)
Affinity DataIC50: 6.40nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM376999(US10259816, Compound 18 | 7-[2-Methoxy-4-trifluoro...)
Affinity DataIC50: 9.10nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM376997(7-(2-Ethoxyphenyl)-6-methyl-N-[4-(piperidin-4-yl)-...)
Affinity DataIC50: 9.30nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM377018(US10259816, Compound 43 | N-[2,2-dimethyl-4-(piper...)
Affinity DataIC50: 10.9nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM377002(US10259816, Compound 23 | 8-(2-Methoxyphenyl)-N-[4...)
Affinity DataIC50: 12nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM377015(US10259816, Compound 40 | 7-{[8-(4-Fluoro-2-methox...)
Affinity DataIC50: 12nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM377000(US10259816, Compound 20 | N-[2-methoxy-4-(piperidi...)
Affinity DataIC50: 12.8nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM436065(US10611770, Compound 29 | 8-(5-Fluoro-2-methoxyphe...)
Affinity DataIC50: 14nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM377008(US10259816, Compound 30 | 8-[2-Methoxy-4-(trifluor...)
Affinity DataIC50: 14nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM377012(US10259816, Compound 34 | 8-(4-Methylsulfonyl-2-me...)
Affinity DataIC50: 14nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM436050(US10611770, Compound 3 | 7-(2,3-Dihydro-1-benzofur...)
Affinity DataIC50: 14nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM377004(US10259816, Compound 25 | 8-(2-Methoxyphenyl)-N-[3...)
Affinity DataIC50: 27nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM436052(US10611770, Compound 11 | 7-(2-Methylphenyl)-N-[4-...)
Affinity DataIC50: 27.7nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM377006(US10259816, Compound 28 | 8-(4-Fluoro-2-methoxyphe...)
Affinity DataIC50: 34nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM377001(US10259816, Compound 22 | 6-Fluoro-8-(2-methoxyphe...)
Affinity DataIC50: 34nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM377010(US10259816, Compound 32 | 8-{2-Methoxy-4-[(morphol...)
Affinity DataIC50: 35nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM377003(US10259816, Compound 24 | N-[2,2-Dimethyl-4-(piper...)
Affinity DataIC50: 36nMAssay Description:Buffer preparation: 50 mM HEPES, pH 7.5, 0.00015% Brij-35.The compound was configured as a concentration gradient in 100% DMSO and added to a 384-wel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2020
Entry Details
Go to US Patent